- Report
- August 2022
- 240 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- January 2022
- 224 Pages
Global
From €6675EUR$6,950USD£5,747GBP
- Report
- March 2021
- 100 Pages
Global
From €4322EUR$4,500USD£3,721GBP
- Report
- August 2022
- 115 Pages
Global
From €4322EUR$4,500USD£3,721GBP
- Report
- September 2019
- 29 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Drug Pipelines
- March 2019
- 111 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Report
- March 2019
- 20 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Report
- March 2019
- 24 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Report
- March 2019
- 19 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Drug Pipelines
- February 2020
- 66 Pages
Global
From €3362EUR$3,500USD£2,894GBP
- Report
- March 2019
- 30 Pages
Global
€9605EUR$10,000USD£8,269GBP
- Report
- May 2023
- 80 Pages
Global
From €3500EUR$3,904USD£3,119GBP
- Report
- August 2022
- 50 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- May 2024
- 50 Pages
Global
From €2545EUR$2,650USD£2,191GBP
- Report
- May 2024
- 50 Pages
Global
From €2545EUR$2,650USD£2,191GBP
Sunitinib is an oncology drug used to treat a variety of cancers, including gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain proteins that can cause cancer cells to grow and divide. Sunitinib is typically administered orally, and is available in both capsule and tablet form.
Sunitinib is a relatively new drug, having been approved by the US Food and Drug Administration in 2006. It has since become a popular treatment option for many types of cancer, due to its effectiveness and relatively low side effects. Sunitinib is also used in combination with other drugs to treat certain types of cancer, such as advanced renal cell carcinoma.
Some of the companies in the Sunitinib market include Pfizer, Novartis, and AstraZeneca. These companies manufacture and distribute the drug, as well as provide support and resources for patients and healthcare professionals. Show Less Read more